Skip to main content
Evidence Snapshot

TRAF2 and NCK-interacting protein kinase

CHEMBL4527 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:43Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4527
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats TRAF2 and NCK-interacting protein kinase as ChEMBL target CHEMBL4527, mapped to UniProt Q9UKE5. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
TRAF2 and NCK-interacting protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4527
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9UKE5
TRAF2 and NCK-interacting protein kinase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why TRAF2 and NCK-interacting protein kinase matters

As of 2026-09-14

TRAF2 and NCK-interacting protein kinase is reviewed as TRAF2 and NCK-interacting protein kinase (UniProt Q9UKE5); the current evidence base includes 16 approved drugs, 1217 compounds, and 244 assays, with lead potency reaching pChEMBL 9.9.

Protein context
TRAF2 and NCK-interacting protein kinase

TRAF2 and NCK-interacting protein kinase Sequence length is 1360 aa.

Review this target as TRAF2 and NCK-interacting protein kinase, mapped to UniProt Q9UKE5. Sequence length is 1360 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9UKE5 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 1217 compounds, and 244 assays for this target. The dominant activity type is IC50. CHEMBL4760558 is the current potency anchor at pChEMBL 9.9.

Use CHEMBL4760558 as the tractability anchor when discussing potency (pChEMBL 9.9).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 9.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why TRAF2 and NCK-interacting protein kinase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9UKE5, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1217
Total Compounds
244
Total Assays
16
Approved Drugs
IC50: 586.0, KI: 2.0, KD: 399.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4760558
 9.9 IC50 —
No preferred name
CHEMBL4749291
 9.9 IC50 —
No preferred name
CHEMBL4762464
 9.7 IC50 —
No preferred name
CHEMBL4759123
 9.7 IC50 —
No preferred name
CHEMBL4744045
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
QUIZARTINIB
CHEMBL576982
 2023
PACRITINIB
CHEMBL2035187
 2022
NERATINIB
CHEMBL180022
 2017
LENVATINIB
CHEMBL1289601
 2015
NINTEDANIB
CHEMBL502835
 2014
BOSUTINIB
CHEMBL288441
 2012
AXITINIB
CHEMBL1289926
 2012
PONATINIB
CHEMBL1171837
 2012
PAZOPANIB
CHEMBL477772
 2009
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:43Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4527